"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 4 | 1 | 5 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 0 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 1 | 1 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 0 | 2 | 2 |
| 2018 | 3 | 4 | 7 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Safety and feasibility of intravenous sotalol loading for the prevention of ventricular arrhythmias. J Interv Card Electrophysiol. 2024 Oct; 67(7):1647-1655.
-
Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. Circulation. 2023 04 11; 147(15):e676-e698.
-
Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay. J Cardiovasc Electrophysiol. 2023 03; 34(3):502-506.
-
A systematic review and meta-analysis comparing radiofrequency catheter ablation with medical therapy for ventricular tachycardia in patients with ischemic and non-ischemic cardiomyopathies. J Interv Card Electrophysiol. 2023 Jan; 66(1):161-175.
-
Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and Rhythm Control Strategies. Am J Cardiovasc Drugs. 2022 Sep; 22(5):475-496.
-
Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation. J Cardiovasc Transl Res. 2021 06; 14(3):492-502.
-
Catheter Ablation for Atrial Fibrillation in 2019. JAMA. 2019 08 20; 322(7):686-687.
-
A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2019 08; 42(8):1146-1154.
-
Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. Pacing Clin Electrophysiol. 2019 06; 42(6):694-704.
-
Impact of Atrial Fibrillation Ablation on Recurrent Hospitalization: A Nationwide Cohort Study. JACC Clin Electrophysiol. 2019 03; 5(3):330-339.